Literature DB >> 7016157

A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma.

N M Bleehen, C R Wiltshire, P N Plowman, J V Watson, J R Gleave, A E Holmes, W S Lewin, C S Treip, T D Hawkins.   

Abstract

The results are reported of a small clinical trial carried out to assess the potential value of the hypoxic cell radiosensitizer misonidazole in the radiation treatment of Grade 3 and 4 supratentorial astrocytomas. A total of 55 patients were randomly allocated to one of 3 treatment groups. No significant differences were seen between the median survivals of patients in the 2 control radiation groups and that of the third group in which oral misonidazole at a dose of 3 g/m2 preceded each of 4 weekly radiation doses. Possible reasons why no improvement was seen are discussed in detail.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7016157      PMCID： PMC2010639          DOI： 10.1038/bjc.1981.64

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  26 in total

1.  Radiosensitizers of hypoxic cells in solid tumors.

Authors:  J F Fowler; G E Adams; J Denekamp
Journal:  Cancer Treat Rev       Date:  1976-12       Impact factor: 12.111

Review 2.  Combined modality therapy for intracranial tumors.

Authors:  H J Bloom
Journal:  Cancer       Date:  1975-01       Impact factor: 6.860

3.  Hyperbaric oxygen and radiation therapy in the management of glioblastoma.

Authors:  C H Chang
Journal:  Natl Cancer Inst Monogr       Date:  1977-12

4.  Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations.

Authors:  A J Gray; S Dische; G E Adams; I R Flockhart; J L Foster
Journal:  Clin Radiol       Date:  1976-04       Impact factor: 2.350

5.  A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma.

Authors:  M J Garrett; H J Hughes; L S Freedman
Journal:  Clin Oncol       Date:  1978-03

6.  The treatment of glioblastoma multiforme of the brain.

Authors:  R Jelsma; P C Bucy
Journal:  J Neurosurg       Date:  1967-11       Impact factor: 5.115

7.  A simplification in the use of the NSD concept in practical radiotherapy.

Authors:  C G Orton; F Ellis
Journal:  Br J Radiol       Date:  1973-07       Impact factor: 3.039

8.  Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography.

Authors:  P Workman; C J Little; T R Marten; A D Dale; R J Ruane; I R Flockhart; N M Bleehen
Journal:  J Chromatogr       Date:  1978-05-01

9.  Radiation and high-dose metronidazole in supratentorial glioblastomas.

Authors:  R Urtasun; P Band; J D Chapman; M L Feldstein; B Mielke; C Fryer
Journal:  N Engl J Med       Date:  1976-06-17       Impact factor: 91.245

10.  Neuromuscular disorder associated with a defect in mitochondrial energy supply.

Authors:  D L Schotland; S DiMauro; E Bonilla; A Scarpa; C P Lee
Journal:  Arch Neurol       Date:  1976-07
View more
  6 in total

Review 1.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

Review 2.  Value of 11C-methionine PET in imaging brain tumours and metastases.

Authors:  Andor W J M Glaudemans; Roelien H Enting; Mart A A M Heesters; Rudi A J O Dierckx; Ronald W J van Rheenen; Annemiek M E Walenkamp; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-12       Impact factor: 9.236

3.  Phase I clinical trial of intracarotid bis-chloroethylnitrosourea (BCNU) and 2' dioxy-5-fluorouridine (FUDR) in malignant astrocytomas.

Authors:  T I Mughal; L M Glode; T J Braun; W Klingensmith; J M Geier; G W Kindt
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

4.  Anomalous patterns of nitroimidazole binding adjacent to necrosis in human glioma xenografts: possible role of decreased oxygen consumption.

Authors:  M B Parliament; A J Franko; M J Allalunis-Turner; B W Mielke; C L Santos; B G Wolokoff; J R Mercer
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.

Authors:  Maria Sandström; Mikael Johansson; Per Bergström; A Tommy Bergenheim; Roger Henriksson
Journal:  J Neurooncol       Date:  2008-01-29       Impact factor: 4.130

6.  The role of dexamethasone in the modification of misonidazole pharmacokinetics.

Authors:  D H Jones; N M Bleehen; P Workman; M I Walton
Journal:  Br J Cancer       Date:  1983-10       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.